Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Infante

Showing results (271-280 of 299) with videos related to

Pageof 30
Sort By:
Journal for Immunotherapy of Cancer|February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trialHyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.
Investigational New Drugs|September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2016
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung CancerDavid R Gandara, Natasha Leighl, Jean-Pierre Delord, et al.
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.
Communications Biology|October 26, 2022
Chromosome-scale genome assembly of the brown anole (Anolis sagrei), an emerging model speciesAnthony J Geneva, Sungdae Park, Dan G Bock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter StudyLeora Horn, Jeffrey R Infante, Karen L Reckamp, et al.
Prostate Cancer and Prostatic Diseases|July 14, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancerCharles G Drake, Russell K Pachynski, Sumit K Subudhi, et al.
Cancer|January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanomaPatrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.
British Journal of Cancer|February 3, 2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitorJohanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, et al.
Pageof 30

Showing results (271-280 of 299) with videos related to

Sort By:
Pageof 30
Journal for Immunotherapy of Cancer|February 6, 2019
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trialHyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, et al.
Investigational New Drugs|September 10, 2020
Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)J Randolph Hecht, Kyriakos P Papadopoulos, Gerald S Falchook, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2021
Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53Mansoor N Saleh, Manish R Patel, Todd M Bauer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 24, 2016
A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung CancerDavid R Gandara, Natasha Leighl, Jean-Pierre Delord, et al.
The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.
Communications Biology|October 26, 2022
Chromosome-scale genome assembly of the brown anole (Anolis sagrei), an emerging model speciesAnthony J Geneva, Sungdae Park, Dan G Bock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter StudyLeora Horn, Jeffrey R Infante, Karen L Reckamp, et al.
Prostate Cancer and Prostatic Diseases|July 14, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancerCharles G Drake, Russell K Pachynski, Sumit K Subudhi, et al.
Cancer|January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanomaPatrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.
British Journal of Cancer|February 3, 2017
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitorJohanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, et al.
Pageof 30